Caspian Healthcare › Obesity › Stopping
This is the question everyone asks last and should ask first. Almost no page in India or anywhere else gives an actual answer, so here is one, including the parts you will not like.
Two trials answer this directly, and they answer it in the same direction.
And it is not only the weight. Waist, blood pressure, non-HDL cholesterol and fasting insulin all moved back towards where they started, roughly in proportion to how much weight came back. The metabolic benefit is rented, not bought.
The honest framing. Obesity behaves like high blood pressure. Nobody is surprised that blood pressure rises again when the tablet stops, and nobody calls that a failure of the tablet. This is the same. These are not treatments that reset a set point and then let you walk away. Plan for a long course, or plan a structured exit, but do not plan on a short course with a permanent result.
Because they are real reasons. Cost, most commonly and by a long way. A planned pregnancy, which requires stopping about two months beforehand. Side effects that did not settle. Reaching a weight where the risk that justified the treatment has gone. Or simply having decided that indefinite treatment is not what they want, which is a legitimate choice for a patient to make.
Real world data are worth knowing here: somewhere between a third and a half of people are no longer on treatment at one year, and the dominant reasons are cost and supply rather than side effects. If you stop, you will be in ordinary company.
There is no trial telling us the best way to come off these treatments. Nobody has run it. What follows is a practical protocol built on what is known about how regain happens, and it is what we use. Treat it as considered clinical practice, not as proven fact.
The reason this page exists at the point in the reading order that it does. Read it before starting, not at the end. If you know now that this is a long term commitment, you can make a very different and much better decision about which treatment to begin, what you can sustain, and whether to start at all. A treatment you can continue beats a better treatment you will have to stop.
Sources: STEP-1 extension, Wilding JPH et al, Diabetes, Obesity and Metabolism, 2022. SURMOUNT-4, JAMA, 2023, and the post-hoc cardiometabolic analysis, JAMA Internal Medicine, 2025. Joint nutrition advisory, 2025.
Every number here comes from a named, published clinical trial and is reported as what happened to the people in that trial. None of it is a result from this clinic, a prediction for you, or a promise. Trial populations are selected and individual results vary widely. The trials are named in the reference line above so that you, or any doctor, can look them up.
If you want to talk about what any of it means for your own situation, our contact details and consulting hours are at the bottom of every page in this section, and our fees are published in full on the cost page.